<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068312</url>
  </required_header>
  <id_info>
    <org_study_id>VX16-770-127</org_study_id>
    <nct_id>NCT03068312</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older and Have Either a 3849 + 10KB C→T or D1152H-CFTR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of ivacaftor treatment in subjects with CF 6 years of
      age and older who have a 3849 + 10KB C→T or D1152H CFTR mutation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Anticipated">September 25, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 25, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lung clearance index 2.5</measure>
    <time_frame>from baseline through 8 weeks</time_frame>
    <description>LCI2.5; calculated as lung volume turnovers required to reach 2.5% of the starting nitrogen [N2] concentration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Sequence 1: First Ivacaftor Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive Ivacaftor, 150 mg every 12 hours (q12h) for 8 weeks in Treatment Period 1 followed by Placebo matching Ivacaftor for 8 weeks in Treatment Period 2. A washout period of 8 weeks will be maintained between the 2 periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: First Placebo Then Ivacaftor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive Placebo matching to Ivacaftor for 8 weeks in Treatment Period 1 followed by Ivacaftor 150 mg q12h for 8 weeks in Treatment Period 2. A washout period of 8 weeks will be maintained between the 2 periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <description>Ivacaftor, 150 mg every 12 hours (q12h)</description>
    <arm_group_label>Sequence 1: First Ivacaftor Then Placebo</arm_group_label>
    <arm_group_label>Sequence 2: First Placebo Then Ivacaftor</arm_group_label>
    <other_name>IVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to Ivacaftor</description>
    <arm_group_label>Sequence 1: First Ivacaftor Then Placebo</arm_group_label>
    <arm_group_label>Sequence 2: First Placebo Then Ivacaftor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF based on protocol-specified clinical features and at least
             one of the following: increased sweat chloride level, identification of 2 CF causing
             mutations, or demonstration of abnormal nasal epithelial ion transport.

          -  A 3849 + 10KB C→T or D1152H mutation on at least 1 CFTR allele.

          -  FEV1 ≥40% of predicted and ≤105% of predicted at screening.

        Exclusion Criteria:

          -  A G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H
             mutation.

          -  History of any illness or any clinical condition that, in the opinion of the
             investigator, might confound the results of the study or pose an additional risk in
             administering study drug to the subject.

          -  Ongoing or prior participation in an investigational drug study within 30 days before
             the Screening Visit.

          -  Protocol-specified abnormal laboratory values at the Screening Visit

          -  For subjects &lt;18 years of age at the Screening Visit, evidence of cataract/lens
             opacity determined to be clinically significant by the ophthalmologist or optometrist
             during the ophthalmologic examination (OE) at the Screening Visit.

          -  Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A,
             including consumption of certain herbal medications and certain fruit and fruit
             juices, within 14 days before Day 1.

          -  Pregnant, breastfeeding, or planning to become pregnant during the study.

          -  Sexually active subjects of reproductive potential must be willing to use appropriate
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>July 28, 2017</last_update_submitted>
  <last_update_submitted_qc>July 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

